The goal of this multi-centre international study was to evaluate the frequency of PR3-ANCA in PSC patients as measured by ELISA and a new chemiluminescence immunoassay (CIA) and to determine clinical correlations with PR3-ANCA. The gene discussed is PRTN3; the disease is pancreatic serous cystadenoma.